Christina Marciniak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christina Marciniak has a total of 246 co-authors. Here are the top co-authors by number of shared publications:
Reinhard Hiersemenzel
Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany
12 shared publicationsAngelika Hanschmann
Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany
10 shared publicationsMichael C. Munin
Department of Physical Medicine and Rehabilitation, University of Pittsburgh School of Medicine, Pittsburgh, PA
10 shared publicationsAllison Brashear
Department of Neurology, Wake Forest School of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC
8 shared publications- Deborah Gaebler-Spira
Shirley Ryan AbilityLab, Feinberg School of Medicine Northwestern University Chicago Illinois USA
7 shared publications Elie Elovic
Renown Rehabilitation Hospital Reno NV United States
6 shared publications
Latest Publications
- Open Access
- 30 October 2025
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 68 (3) , 313-331
Gastroenterological disorders and hepatic disease in adults with cerebral palsy: A systematic review
Aim: To describe the incidence, prevalence, and prognostic factors for gastroenterological disorders and hepatic disease in adults with cerebral palsy (CP), and to examine the effectiveness of any screening or interventions. Method: Six databases were searched for articles published in any language since 1990 meeting eligibility criteria, defined for each of five objectives. Two independent reviewers screened study titles, abstracts, and full texts for inclusion. Results: Thirty‐two reports of 30 unique samples, including 10 to 16 818 adults, were identified. Twenty‐five reported prevalence of at least one of the following: gastroesophageal reflux disease (GERD) (prevalence 3%–42%; seven studies), constipation (4%–67%; seven studies), dysphagia (6%–77%; 12 studies), fecal incontinence (6%–29%; three studies), dental/oral cavity disorders (25%–53%; five studies), and aggregated hepatic diseases (1%–6%; seven studies). The prevalences of GERD, dysphagia, and hepatic disease were higher in adults with CP than in those without. The prevalence of fecal incontinence was greater in people classified as having CP in higher Gross Motor Function Classification System levels. No incidence studies were identified. Four intervention studies addressing oral/dental health or dysphagia were found, but certainty of evidence was low to very low. Interpretation: The prevalence of specific gastroenterological disorders and hepatic disease varies across studies in adults with CP. Evidence for intervention efficacy in their management is of very low quality to absent.
- 30 October 2025
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 68 (3) , 313-331
Open AccessGastroenterological disorders and hepatic disease in adults with cerebral palsy: A systematic review
Aim: To describe the incidence, prevalence, and prognostic factors for gastroenterological disorders and hepatic disease in adults with cerebral palsy (CP), and to examine the effectiveness of any screening or interventions. Method: Six databases were searched for articles published in any language since 1990 meeting eligibility criteria, defined for each of five objectives. Two independent reviewers screened study titles, abstracts, and full texts for inclusion. Results: Thirty‐two reports of 30 unique samples, including 10 to 16 818 adults, were identified. Twenty‐five reported prevalence of at least one of the following: gastroesophageal reflux disease (GERD) (prevalence 3%–42%; seven studies), constipation (4%–67%; seven studies), dysphagia (6%–77%; 12 studies), fecal incontinence (6%–29%; three studies), dental/oral cavity disorders (25%–53%; five studies), and aggregated hepatic diseases (1%–6%; seven studies). The prevalences of GERD, dysphagia, and hepatic disease were higher in adults with CP than in those without. The prevalence of fecal incontinence was greater in people classified as having CP in higher Gross Motor Function Classification System levels. No incidence studies were identified. Four intervention studies addressing oral/dental health or dysphagia were found, but certainty of evidence was low to very low. Interpretation: The prevalence of specific gastroenterological disorders and hepatic disease varies across studies in adults with CP. Evidence for intervention efficacy in their management is of very low quality to absent.
- 6 May 2021
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 63 (10) , 1221-1228
Diet quality in adults with cerebral palsy: a modifiable risk factor for cardiovascular disease prevention
Aim: To assess diet quality and its relationship with cardiovascular health measures for adults with cerebral palsy (CP).Method: A convenience sample of 45 adults with CP (26 females, 19 males; mean age 35y 10mo [SD 14y 9mo]). were recruited for this cross‐sectional study. Demographic, medical, and Gross Motor Function Classification System (GMFCS) information were obtained through in‐person visits. Participants completed two 24‐hour dietary recalls using the Automated Self‐Administered 24‐hour Dietary Assessment Tool. Specific macronutrient intake was compared to 2015 to 2020 US Department of Agriculture (USDA) guidelines. Other data included body mass index (BMI), waist‐to‐hip ratio (WHR), blood pressure, and hemoglobin A1c (HgA1c;n=43).Results: Adults across GMFCS levels I to V were enrolled, 20 participants were in GMFCS levels IV or V. Mean calorie intake was 1777.91/day (SD 610.54), while sodium intake was 3261.75mg/day (SD 1484.92). Five participants met USDA vegetable and seven fruit guidelines. None met whole grain targets. Sixteen were overweight/obese by BMI. Sixteen participants without hypertension diagnoses had elevated blood pressure and nine had abnormal HgA1c without prediabetes/diabetes history. Percent calories from saturated fat was inversely associated with WHR in unadjusted and adjusted models (p=0.002 and p=0.003 respectively); all other dietary recommendations assessed (total calories, sodium, and sugar) were non‐significant. Post hoc analyses were unchanged using 2020 to 2025 USDA guidelines.Interpretation: Assessment of nutrient intake and diet quality is feasible and warrants further study in adults with CP, as USDA guidelines are largely unmet. What this paper adds: Adults with cerebral palsy (CP) do not meet US Department of Agriculture dietary quality recommendations. Prediabetes and hypertension may be common, but unrecognized, in adults with CP. Screening for nutrient intake and diet quality should be performed to facilitate nutritional counseling.
- 6 May 2021
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 63 (10) , 1221-1228
Diet quality in adults with cerebral palsy: a modifiable risk factor for cardiovascular disease prevention
Aim: To assess diet quality and its relationship with cardiovascular health measures for adults with cerebral palsy (CP).Method: A convenience sample of 45 adults with CP (26 females, 19 males; mean age 35y 10mo [SD 14y 9mo]). were recruited for this cross‐sectional study. Demographic, medical, and Gross Motor Function Classification System (GMFCS) information were obtained through in‐person visits. Participants completed two 24‐hour dietary recalls using the Automated Self‐Administered 24‐hour Dietary Assessment Tool. Specific macronutrient intake was compared to 2015 to 2020 US Department of Agriculture (USDA) guidelines. Other data included body mass index (BMI), waist‐to‐hip ratio (WHR), blood pressure, and hemoglobin A1c (HgA1c;n=43).Results: Adults across GMFCS levels I to V were enrolled, 20 participants were in GMFCS levels IV or V. Mean calorie intake was 1777.91/day (SD 610.54), while sodium intake was 3261.75mg/day (SD 1484.92). Five participants met USDA vegetable and seven fruit guidelines. None met whole grain targets. Sixteen were overweight/obese by BMI. Sixteen participants without hypertension diagnoses had elevated blood pressure and nine had abnormal HgA1c without prediabetes/diabetes history. Percent calories from saturated fat was inversely associated with WHR in unadjusted and adjusted models (p=0.002 and p=0.003 respectively); all other dietary recommendations assessed (total calories, sodium, and sugar) were non‐significant. Post hoc analyses were unchanged using 2020 to 2025 USDA guidelines.Interpretation: Assessment of nutrient intake and diet quality is feasible and warrants further study in adults with CP, as USDA guidelines are largely unmet. What this paper adds: Adults with cerebral palsy (CP) do not meet US Department of Agriculture dietary quality recommendations. Prediabetes and hypertension may be common, but unrecognized, in adults with CP. Screening for nutrient intake and diet quality should be performed to facilitate nutritional counseling.
- Open Access
- 16 December 2019
- Published by Oxford University Press (OUP) in Physical Therapy
- Vol. 99 (12) , 1644-1655
Using Implementation Frameworks to Provide Proactive Physical Therapy for People With Parkinson Disease: Case Report
Background and Purpose: European clinical practice guidelines recommend physical therapy for people with Parkinson disease (PD) soon after diagnosis to provide education, physical activity advice, and individualized interventions when needed. However, therapy is frequently not used until after gait and balance problems occur. The purpose of this administrative case study is to present the application of a proactive physical therapy (PAPT) approach at 1 rehabilitation center using implementation frameworks to support the (1) implementation process, (2) determinants of implementation success, and (3) implementation evaluation. Case Description: The PAPT program targeted people with PD before the onset of significant mobility dysfunction. It was initiated in 1 outpatient neurological rehabilitation center. The program used shared decision-making to promote long-term maintenance of independent exercise. The Knowledge-to-Action Framework was used by champions to plan implementation processes. Implementation barriers were addressed using the Consolidated Framework for Implementation Research. The program was evaluated using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework with mixed methods. Outcomes: In the program’s first year, 38 people were referred, 28 were evaluated, and 20 participated in the 6-month program evaluation. Following PAPT, the number of participants reporting regular participation in aerobic, strengthening, and flexibility exercise approximately doubled, while those engaging in balance activities increased from 1 to 8. They reported a median of 140 minutes of aerobic exercise per week. Implementation barriers included location, insurance coverage, and difficulty scheduling long-term follow-up visits. Participants reported physical and emotional benefits of the program. Discussion: Implementation frameworks assisted with the implementation and evaluation of a PAPT delivery model that helped people with PD to increase and maintain independent exercise participation.
- 16 December 2019
- Published by Oxford University Press (OUP) in Physical Therapy
- Vol. 99 (12) , 1644-1655
Open AccessUsing Implementation Frameworks to Provide Proactive Physical Therapy for People With Parkinson Disease: Case Report
Background and Purpose: European clinical practice guidelines recommend physical therapy for people with Parkinson disease (PD) soon after diagnosis to provide education, physical activity advice, and individualized interventions when needed. However, therapy is frequently not used until after gait and balance problems occur. The purpose of this administrative case study is to present the application of a proactive physical therapy (PAPT) approach at 1 rehabilitation center using implementation frameworks to support the (1) implementation process, (2) determinants of implementation success, and (3) implementation evaluation. Case Description: The PAPT program targeted people with PD before the onset of significant mobility dysfunction. It was initiated in 1 outpatient neurological rehabilitation center. The program used shared decision-making to promote long-term maintenance of independent exercise. The Knowledge-to-Action Framework was used by champions to plan implementation processes. Implementation barriers were addressed using the Consolidated Framework for Implementation Research. The program was evaluated using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework with mixed methods. Outcomes: In the program’s first year, 38 people were referred, 28 were evaluated, and 20 participated in the 6-month program evaluation. Following PAPT, the number of participants reporting regular participation in aerobic, strengthening, and flexibility exercise approximately doubled, while those engaging in balance activities increased from 1 to 8. They reported a median of 140 minutes of aerobic exercise per week. Implementation barriers included location, insurance coverage, and difficulty scheduling long-term follow-up visits. Participants reported physical and emotional benefits of the program. Discussion: Implementation frameworks assisted with the implementation and evaluation of a PAPT delivery model that helped people with PD to increase and maintain independent exercise participation.
IncobotulinumtoxinA Treatment in Upper‐Limb Poststroke Spasticity in the Open‐Label Extension Period of PURE: Efficacy in Passive Function, Caregiver Burden, and Quality of Life
Background: Poststroke spasticity affects motor function and the ability to perform activities of daily living, with the potential to affect quality of life (QoL) and increase caregiver burden.Objective: To investigate the effect of repeated incobotulinumtoxinA treatment on spasticity‐associated functional disability, caregiver burden, and QoL in the 36‐week open‐label extension of the phase 3 PURE study (NCT01392300).Design: Open‐label extension period of a prospective, double‐blind, placebo‐controlled, randomized, multicenter study.Setting: Forty‐six investigation sites in seven countries (Czech Republic, Germany, Hungary, India, Poland, Russia, United States).Participants: Adults, aged 18‐80 years, ≥12 months since last botulinum neurotoxin injection or entirely toxin naïve, with median poststroke upper‐limb spasticity of >2 years' duration.Methods: Participants who completed the 12‐week, double‐blind main period could enter the open‐label extension and receive up to three additional incobotulinumtoxinA treatments (fixed total dose 400 U at 12‐week intervals) into the affected muscles of one upper limb.Main Outcome Measures: Functional disability (Disability Assessment Scale; DAS), caregiver burden (Carer Burden Scale), and quality of life (QoL; EuroQol [EQ] 5‐dimensions three‐level [EQ‐5D‐3L]).Results: The open‐label extension included 296 treated patients. Mean DAS score for the principal target domain improved significantly from the main period baseline to the end‐of‐study visit (P < .0001). Carer Burden Scale scores also significantly improved from the main period baseline to the end‐of‐study visit (P < .05 for all caregiving activities except “applying a splint”). At the end‐of‐study visit, versus the main period baseline, 19.7%‐33.3% of patients experienced improvements for each parameter on the EQ‐5D‐3L, except “mobility,” with significant improvement in EQ‐5D visual analog scale scores (P < .001).Conclusions: Repeated incobotulinumtoxinA treatments at 12‐week intervals in participants with chronic poststroke upper‐limb spasticity resulted in significant improvements in QoL, as well as significant reductions in upper‐limb functional disability and caregiver burden.
IncobotulinumtoxinA Treatment in Upper‐Limb Poststroke Spasticity in the Open‐Label Extension Period of PURE: Efficacy in Passive Function, Caregiver Burden, and Quality of Life
Background: Poststroke spasticity affects motor function and the ability to perform activities of daily living, with the potential to affect quality of life (QoL) and increase caregiver burden.Objective: To investigate the effect of repeated incobotulinumtoxinA treatment on spasticity‐associated functional disability, caregiver burden, and QoL in the 36‐week open‐label extension of the phase 3 PURE study (NCT01392300).Design: Open‐label extension period of a prospective, double‐blind, placebo‐controlled, randomized, multicenter study.Setting: Forty‐six investigation sites in seven countries (Czech Republic, Germany, Hungary, India, Poland, Russia, United States).Participants: Adults, aged 18‐80 years, ≥12 months since last botulinum neurotoxin injection or entirely toxin naïve, with median poststroke upper‐limb spasticity of >2 years' duration.Methods: Participants who completed the 12‐week, double‐blind main period could enter the open‐label extension and receive up to three additional incobotulinumtoxinA treatments (fixed total dose 400 U at 12‐week intervals) into the affected muscles of one upper limb.Main Outcome Measures: Functional disability (Disability Assessment Scale; DAS), caregiver burden (Carer Burden Scale), and quality of life (QoL; EuroQol [EQ] 5‐dimensions three‐level [EQ‐5D‐3L]).Results: The open‐label extension included 296 treated patients. Mean DAS score for the principal target domain improved significantly from the main period baseline to the end‐of‐study visit (P < .0001). Carer Burden Scale scores also significantly improved from the main period baseline to the end‐of‐study visit (P < .05 for all caregiving activities except “applying a splint”). At the end‐of‐study visit, versus the main period baseline, 19.7%‐33.3% of patients experienced improvements for each parameter on the EQ‐5D‐3L, except “mobility,” with significant improvement in EQ‐5D visual analog scale scores (P < .001).Conclusions: Repeated incobotulinumtoxinA treatments at 12‐week intervals in participants with chronic poststroke upper‐limb spasticity resulted in significant improvements in QoL, as well as significant reductions in upper‐limb functional disability and caregiver burden.
- 10 October 2019
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 62 (3) , 379-385
Spasticity and pain in adults with cerebral palsy
Aim: To evaluate whether spasticity measures are related to pain in adults with cerebral palsy (CP).Method: This cross‐sectional study recruited individuals aged 16 to 89 years with a diagnosis of CP. Participants completed the Penn Spasm Frequency Scale (PSFS), Brief Pain Inventory (BPI), and PROMIS Pain Interference measures. The Modified Ashworth Scale (MAS) and Tardieu spasticity angles of six joints were rated and summed to composite MAS and Tardieu scores for each participant. Associations between spasticity and pain measures were evaluated.Results: Forty‐seven participants (27 females, 20 males) with a mean age of 35 years 7 months (range 18–77y) spanning all Gross Motor Function Classification System (GMFCS) levels were included. Twenty‐six participants reported their average pain level on BPI as greater than 0 over the past week (median pain level 4.0). Median PSFS was 1.0 (range 0.0–1.0) and this correlated with average BPI and Pain Interference T scores (median 40.7; ρ=0.33 and ρ=0.31 respectively [both p=0.01]). When adjusted for pain medication use and age, MAS correlated with BPI (ρ=0.30; p=0.04). Other pain and spasticity measures, or GMFCS level, were not significantly related with pain interference or BPI rating. Age was weakly associated with BPI (slope=0.10; p<0.01).Interpretation: PROMIS Pain Interference was lower than population‐based norms. Patient‐rated spasm frequency demonstrated better association with pain levels and interference than physician‐rated MAS and Tardieu.What this paper adds: Pain was not associated with Gross Motor Function Classification System level. Pain increased with age, as anticipated. Self‐reported spasm scores were associated with increased pain in contrast to clinical examination scales. Adjusted, summed spasticity on the Modified Ashworth Scale was associated with pain scores on the Brief Pain Inventory. Although pain is experienced by adults with cerebral palsy, pain did not interfere with activities.
- 10 October 2019
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 62 (3) , 379-385
Spasticity and pain in adults with cerebral palsy
Aim: To evaluate whether spasticity measures are related to pain in adults with cerebral palsy (CP).Method: This cross‐sectional study recruited individuals aged 16 to 89 years with a diagnosis of CP. Participants completed the Penn Spasm Frequency Scale (PSFS), Brief Pain Inventory (BPI), and PROMIS Pain Interference measures. The Modified Ashworth Scale (MAS) and Tardieu spasticity angles of six joints were rated and summed to composite MAS and Tardieu scores for each participant. Associations between spasticity and pain measures were evaluated.Results: Forty‐seven participants (27 females, 20 males) with a mean age of 35 years 7 months (range 18–77y) spanning all Gross Motor Function Classification System (GMFCS) levels were included. Twenty‐six participants reported their average pain level on BPI as greater than 0 over the past week (median pain level 4.0). Median PSFS was 1.0 (range 0.0–1.0) and this correlated with average BPI and Pain Interference T scores (median 40.7; ρ=0.33 and ρ=0.31 respectively [both p=0.01]). When adjusted for pain medication use and age, MAS correlated with BPI (ρ=0.30; p=0.04). Other pain and spasticity measures, or GMFCS level, were not significantly related with pain interference or BPI rating. Age was weakly associated with BPI (slope=0.10; p<0.01).Interpretation: PROMIS Pain Interference was lower than population‐based norms. Patient‐rated spasm frequency demonstrated better association with pain levels and interference than physician‐rated MAS and Tardieu.What this paper adds: Pain was not associated with Gross Motor Function Classification System level. Pain increased with age, as anticipated. Self‐reported spasm scores were associated with increased pain in contrast to clinical examination scales. Adjusted, summed spasticity on the Modified Ashworth Scale was associated with pain scores on the Brief Pain Inventory. Although pain is experienced by adults with cerebral palsy, pain did not interfere with activities.
- 22 March 2019
- Published by SAGE Publications in Neurorehabilitation and Neural Repair
- Vol. 33 (4) , 245-259
Ultrasound Structural Changes in Triceps Surae After a 1-Year Daily Self-stretch Program: A Prospective Randomized Controlled Trial in Chronic Hemiparesis
Introduction. The effects of long-term stretching (>6 months) in hemiparesis are unknown. This prospective, randomized, single-blind controlled trial compared changes in architectural and clinical parameters in plantar flexors of individuals with chronic hemiparesis following a 1-year guided self-stretch program, compared with conventional rehabilitation alone. Methods. Adults with chronic stroke-induced hemiparesis (time since lesion >1 year) were randomized into 1 of 2, 1-year rehabilitation programs: conventional therapy (CONV) supplemented with the Guided Self-rehabilitation Contract (GSC) program, or CONV alone. In the GSC group, specific lower limb muscles, including plantar flexors, were identified for a diary-based treatment utilizing daily, high-load, home self-stretching. Blinded assessments included (1) ultrasonographic measurements of soleus and medial gastrocnemius (MG) fascicle length and thickness, with change in soleus fascicle length as primary outcome; (2) maximum passive muscle extensibility (XV1, Tardieu Scale); (3) 10-m maximal barefoot ambulation speed. Results. In all, 23 individuals (10 women; mean age [SD], 56 [±12] years; time since lesion, 9 [±8] years) were randomized into either the CONV (n = 11) or GSC (n = 12) group. After 1 year, all significant between-group differences favored the GSC group: soleus fascicle length, +18.1mm [9.3; 29.9]; MG fascicle length, +6.3mm [3.5; 9.1]; soleus thickness, +4.8mm [3.0; 7.7]; XV1 soleus, +4.1° [3.1; 7.2]; XV1 gastrocnemius, +7.0° [2.1; 11.9]; and ambulation speed, +0.07m/s [+0.02; +0.16]. Conclusions. In chronic hemiparesis, daily self-stretch of the soleus and gastrocnemius over 1 year using GSC combined with conventional rehabilitation increased muscle fascicle length, extensibility, and ambulation speed more than conventional rehabilitation alone.
- 22 March 2019
- Published by SAGE Publications in Neurorehabilitation and Neural Repair
- Vol. 33 (4) , 245-259
Ultrasound Structural Changes in Triceps Surae After a 1-Year Daily Self-stretch Program: A Prospective Randomized Controlled Trial in Chronic Hemiparesis
Introduction. The effects of long-term stretching (>6 months) in hemiparesis are unknown. This prospective, randomized, single-blind controlled trial compared changes in architectural and clinical parameters in plantar flexors of individuals with chronic hemiparesis following a 1-year guided self-stretch program, compared with conventional rehabilitation alone. Methods. Adults with chronic stroke-induced hemiparesis (time since lesion >1 year) were randomized into 1 of 2, 1-year rehabilitation programs: conventional therapy (CONV) supplemented with the Guided Self-rehabilitation Contract (GSC) program, or CONV alone. In the GSC group, specific lower limb muscles, including plantar flexors, were identified for a diary-based treatment utilizing daily, high-load, home self-stretching. Blinded assessments included (1) ultrasonographic measurements of soleus and medial gastrocnemius (MG) fascicle length and thickness, with change in soleus fascicle length as primary outcome; (2) maximum passive muscle extensibility (XV1, Tardieu Scale); (3) 10-m maximal barefoot ambulation speed. Results. In all, 23 individuals (10 women; mean age [SD], 56 [±12] years; time since lesion, 9 [±8] years) were randomized into either the CONV (n = 11) or GSC (n = 12) group. After 1 year, all significant between-group differences favored the GSC group: soleus fascicle length, +18.1mm [9.3; 29.9]; MG fascicle length, +6.3mm [3.5; 9.1]; soleus thickness, +4.8mm [3.0; 7.7]; XV1 soleus, +4.1° [3.1; 7.2]; XV1 gastrocnemius, +7.0° [2.1; 11.9]; and ambulation speed, +0.07m/s [+0.02; +0.16]. Conclusions. In chronic hemiparesis, daily self-stretch of the soleus and gastrocnemius over 1 year using GSC combined with conventional rehabilitation increased muscle fascicle length, extensibility, and ambulation speed more than conventional rehabilitation alone.
- Open Access
- 27 November 2018
- Published by Springer Nature in Advances in Therapy
- Vol. 36 (1) , 187-199
IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study
Introduction The objective of the study was to investigate the efficacy and safety of repeated incobotulinumtoxinA injections for the treatment of upper-limb post-stroke spasticity in adults. Methods Adults 18–80 years of age with post-stroke upper-limb spasticity who completed the 12-week randomized, double-blind, placebo-controlled main period (MP) of a phase 3 trial (NCT01392300) were eligible to enrol in the 36-week open-label extension period (OLEX). The OLEX included three treatment cycles at fixed 12-week injection intervals; subjects were injected with 400 U incobotulinumtoxinA into the affected upper limb. Efficacy assessments included evaluation of muscle tone using the Ashworth Scale (AS) and the Global Impression of Change Scale (GICS) assessed by the investigator, subject, and caregiver. The incidence of adverse events (AEs) was monitored throughout the OLEX. Results A total of 296 of 299 subjects (99.0%) who completed the MP received incobotulinumtoxinA in the OLEX, and 248 subjects completed the 36-week OLEX. The proportion of subjects with at least a 1-point improvement in AS score from each incobotulinumtoxinA treatment to the respective 4-week post-injection visit ranged by cycle from 52.3% to 59.2% for wrist flexors, 49.1% to 52.3% for elbow flexors, 59.8% to 64.5% for finger flexors, 35.5% to 41.2% for thumb flexors, and 37.4% to 39.9% for forearm pronators (P < 0.0001 for all). Over 90% of subjects were assessed by the investigator to be at least minimally improved (4 weeks post-injection) on the GICS during each injection cycle; 61.0% in the 1st cycle, 58.2% in the 2nd cycle, and 57.4% in the 3rd cycle were considered much improved or very much improved on the GICS. Three percent of subjects (9/296) reported treatment-related AEs; the most frequently reported were pain in the extremity (n = 2, 0.7%) and constipation (n = 2, 0.7%). Serious AEs were reported by 22 subjects (7.4%); however, none were considered treatment-related. Conclusions Repeated injections of incobotulinumtoxinA for the treatment of post-stroke upper-limb spasticity led to significant improvements in muscle tone and investigator’s global impression of change. Treatment was well tolerated, with no serious treatment-related AEs. Funding Merz Pharmaceuticals GmbH.
- 27 November 2018
- Published by Springer Nature in Advances in Therapy
- Vol. 36 (1) , 187-199
Open AccessIncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study
Introduction The objective of the study was to investigate the efficacy and safety of repeated incobotulinumtoxinA injections for the treatment of upper-limb post-stroke spasticity in adults. Methods Adults 18–80 years of age with post-stroke upper-limb spasticity who completed the 12-week randomized, double-blind, placebo-controlled main period (MP) of a phase 3 trial (NCT01392300) were eligible to enrol in the 36-week open-label extension period (OLEX). The OLEX included three treatment cycles at fixed 12-week injection intervals; subjects were injected with 400 U incobotulinumtoxinA into the affected upper limb. Efficacy assessments included evaluation of muscle tone using the Ashworth Scale (AS) and the Global Impression of Change Scale (GICS) assessed by the investigator, subject, and caregiver. The incidence of adverse events (AEs) was monitored throughout the OLEX. Results A total of 296 of 299 subjects (99.0%) who completed the MP received incobotulinumtoxinA in the OLEX, and 248 subjects completed the 36-week OLEX. The proportion of subjects with at least a 1-point improvement in AS score from each incobotulinumtoxinA treatment to the respective 4-week post-injection visit ranged by cycle from 52.3% to 59.2% for wrist flexors, 49.1% to 52.3% for elbow flexors, 59.8% to 64.5% for finger flexors, 35.5% to 41.2% for thumb flexors, and 37.4% to 39.9% for forearm pronators (P < 0.0001 for all). Over 90% of subjects were assessed by the investigator to be at least minimally improved (4 weeks post-injection) on the GICS during each injection cycle; 61.0% in the 1st cycle, 58.2% in the 2nd cycle, and 57.4% in the 3rd cycle were considered much improved or very much improved on the GICS. Three percent of subjects (9/296) reported treatment-related AEs; the most frequently reported were pain in the extremity (n = 2, 0.7%) and constipation (n = 2, 0.7%). Serious AEs were reported by 22 subjects (7.4%); however, none were considered treatment-related. Conclusions Repeated injections of incobotulinumtoxinA for the treatment of post-stroke upper-limb spasticity led to significant improvements in muscle tone and investigator’s global impression of change. Treatment was well tolerated, with no serious treatment-related AEs. Funding Merz Pharmaceuticals GmbH.
- 1 October 2018
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 99 (10) , e62
Physical Therapy for People With Newly Diagnosed Parkinson's Disease: A Knowledge Translation Research Approach
- 1 October 2018
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 99 (10) , e62
Physical Therapy for People With Newly Diagnosed Parkinson's Disease: A Knowledge Translation Research Approach
- 1 July 2018
- Published by Elsevier in Disability and Health Journal
- Vol. 11 (3) , 435-441
Breast cancer screening in women with cerebral palsy: Could care delivery be improved?
- 1 July 2018
- Published by Elsevier in Disability and Health Journal
- Vol. 11 (3) , 435-441
Breast cancer screening in women with cerebral palsy: Could care delivery be improved?